Literature DB >> 31707394

Clinical Characteristics of Polypoidal Choroidal Vasculopathy and Anti-Vascular Endothelial Growth Factor Treatment Response in Caucasians.

Gregg T Kokame1,2,3,4,5, Keke Liu6,7,8,9, Kelli A Kokame6,7,8, Kyle N Kaneko6,7,8, Jase N Omizo6,7,8.   

Abstract

BACKGROUND/AIMS: To identify the clinical characteristics of polypoidal choroidal vasculopathy (PCV) in Caucasian patients and assess the prevalence of anti-vascular endothelial growth factor (anti-VEGF) resistance.
METHODS: This involved a retrospective chart review of Caucasian patients diagnosed with PCV and utilizing indocyanine green angiography with the scanning laser ophthalmoscope. Data collected included patients' demographics, disease characteristics, and treatment response.
RESULTS: There were 54 eyes of 49 patients with PCV; 51.0% were male and 49.0% were female with a mean age of 72.9 years. Forty-four patients (89.8%) had PCV unilaterally and 10.2% (5 patients) had PCV bilaterally. PCV was located in the macula in 79.6%, in the peripapillary region in 16.7%, and in both regions in 3.7%. PCV commonly presents with serous detachment (66.7%), retinal pigment epithelial detachment (RPED) (51.9%) and subretinal hemorrhage (37.0%). Twenty-nine eyes were included in the treatment response analysis, with 18 eyes (62.1%) showing persistent disease activity after 3 initial injections of anti-VEGF treatment.
CONCLUSION: PCV in Caucasian patients is more often unilateral and presents more commonly in the macular region than the peripapillary region. Serous detachment and RPED are the 2 most common findings. Resistance to current anti-VEGF treatment was noted frequently; it is thus extremely important to identify this subtype of type I subretinal neovascularization.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Age-related macular degeneration; Caucasian; Indocyanine green angiography; Polypoidal choroidal vasculopathy; Subretinal aneurysmal neovascularization

Year:  2019        PMID: 31707394     DOI: 10.1159/000503834

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  2 in total

Review 1.  Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options.

Authors:  Josh O Wallsh; Ron P Gallemore
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

2.  Probabilistic Forecasting of Anti-VEGF Treatment Frequency in Neovascular Age-Related Macular Degeneration.

Authors:  Maximilian Pfau; Soumya Sahu; Rawan Allozi Rupnow; Kathleen Romond; Desiree Millet; Frank G Holz; Steffen Schmitz-Valckenberg; Monika Fleckenstein; Jennifer I Lim; Luis de Sisternes; Theodore Leng; Daniel L Rubin; Joelle A Hallak
Journal:  Transl Vis Sci Technol       Date:  2021-06-01       Impact factor: 3.283

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.